Bayesian Analysis: Bayesian Analysis in Health Economics Bayesian Analysis: Posterior Interval Bayesian Analysis: Prior Distribution
|
|
|
- Lester Barrett
- 6 years ago
- Views:
Transcription
1 Bayesian Analysis Bayesian Analysis Bayesian Analysis Bayesian Analysis Biotechnology Biotechnology Biotechnology Bootstrapping Case Mix Index Clinical Practice Guidelines Study Bias Study Bias Study Bias Study Bias Study Bias Study Bias Study Bias Study Bias Bayesian Analysis Bayesian Analysis: Bayesian Analysis in Health Economics Bayesian Analysis: Posterior Interval Bayesian Analysis: Prior Distribution Biotechnology Biotechnology: Biological Drug Biotechnology: Biopharmaceuticals Bootstrapping Case Mix Index Clinical Practice Guidelines : Randomized : Mega Trial : Firms Trial : Nonorandomized Trial with Contemporaneous Controls : Nonorandomized Trial with Historical Codes : Equivalence Studies : Matched-Pair Design : Clinical Endpoint : Clinical Indicator : Head to Head Comparison Study : Case Report Study : Case-Control Study : Cross-sectional study : Crossover Trial : Crossover Trial Within- Patient Differences : Economic : Open-label trial : Piggyback Study : Bridging Study : Clinical Research Study Study Bias Study Bias: Study Bias Study Bias: Selection Bias Study Bias: Response Bias Study Bias: Information Bias Study Bias: Interviewer Bias Study Bias Study Bias: Site Selection
2 Compliance Compliance Compliance Compliance Compliance Compliance Confounding Conjoint Analysis Contingent Valuation Contingent Valuation Cost Benefit Analysis (CBA) Cost Benefit Analysis (CBA) Cost Benefit Analysis (CBA) Cost Comparison Study Cost Comparison Study Cost Comparison Study Cost Consequence Study Cost Effectiveness Acceptability Curve Cost Measurement Methods Cost Measurement Methods Cost Measurement Methods Bias Compliance: Adherence Compliance: Treatment Persistence Compliance: Electronic Monitoring Compliance: Pill Count Method Compliance: Prescription Refill Rate Compliance: Attendance Confounding Conjoint Analysis Contingent Valuation Contingent Valuation: Willingness to Pay Cost Benefit Analysis (CBA) Cost Benefit Analysis (CBA): Cost-Benefit Ratio Cost Benefit Analysis (CBA): Cost Comparison Study Cost Comparison Study: Cost- Identification Analysis Cost Comparison Study: Discounting Cost Consequence Study Cost Effectiveness Acceptability Curve : Incremental Cost-Effectiveness Ratio (ICER) : Cost- Effectiveness Analysis : Reference Case : Pharmacoeconomics : Costminimization Analysis : Cost-utility Analysis : Discount Rate : : Simple : Extended Cost Measurement Methods Cost Measurement Methods: Human Capital Method Cost Measurement Methods: Friction Cost Method
3 Cost of Illness Study Cost of Illness Study Cost of Illness Study Cost of Illness Study Cost of Illness Study Cost of Illness Study : Costconsequence : Costeffectiveness : Costutility : Costbenefit : Willingness To Pay : Contingent Valuation : Quality-Adjusted Life Years : Health-Year Equivalents Cost of Illness Study Cost of Illness Study: Human Capital Approach Cost of Illness Study: Friction Cost Cost of Illness Study: Cost-Effectiveness Cost of Illness Study: Cost- Cost of Illness Study: Cost-Benefit : Quality-Adjusted Life Years : Cost-Effectiveness Analysis : Standard Gamble : Time Trade-Off : Utilities : Measurement : Health Utilities Index : EuroQol EQ5D : Quality of Well- Being : Disability-Adjusted Life (DALY) : Healthy Year Equivalents : Fixed Costs : Variable Costs : Capital Costs : Average Costs : Incremental Costs
4 Costs Opportunity Costs Decision Analysis Decision Analysis Decision Analysis Decision Analysis Decision Tree Delphi Panel Method Disability Adjusted Life Year (DALY) Disability Adjusted Life Year (DALY) Discounting Disease Management : Marginal Costs : Sunk Costs : Allowable Cost : Maximum Allowable Cost List : Acquisition Cost, Ancillary Cost : Averted Cost : Out of Pocket Costs : Intangible Costs : Indirect Costs : Human Capital Method : Friction Cost Method Costs Opportunity Costs : Diagnosis Related Croup (DRG) : HCFA Common Procedural Coding System (HCPCS) : International Classification Diseases 9 th /10 th Edition Clinical Modification (ICD 9/10 CM) : Major Diagnostic Category (MDC) : National Drug Code (NDC) : Physicians Current Procedural Terminology, Fourth Edition (CPT4) : Resource Intensity Weights (RIWs) Decision Analysis Decision Analysis: Decision Analysis: Expectation Decision Analysis: Cost-Effective Analysis Decision Tree Delphi Panel Method Disability Adjusted Life Year (DALY) Disability Adjusted Life Year (DALY): Quality-Adjusted Life Year Discounting Disease Management
5 Disease Management Disease Management Disease Management Disease Management Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System Drug Interaction Drug Marketing Drug Marketing Drug Research and Development Drug Research and Development Drug Research and Development Drug Research and Development Drug Efficacy Disease Management: Disease Management Support Services Disease Management: Efficient Frontier Disease Management: Cost-Effectiveness Disease Management: Cost- : Simple dominance : Extended dominance : Efficient frontier : Quality-Adjusted Life Years Drug Formulary & Drug Formulary System Drug Formulary & Drug Formulary System: Closed/partially closed formulary Drug Formulary & Drug Formulary System: Open-preferred formulary Drug Formulary & Drug Formulary System: Open-passive formulary Drug Formulary & Drug Formulary System: Tiered co-payment Drug Formulary & Drug Formulary System: Formulary management Drug Interaction Drug Marketing Drug Marketing: Opinion Leader : Pricing Strategy : Catalog Price : AWP : Rebates : Pricing Model : Reference-based Pricing Drug Research and Development Drug Research and Development: Basic Pharmaceutical Research Drug Research and Development: Pre Clinical Research Drug Research and Development: Clinical Research Drug Efficacy : Pharmacovigilance : Adverse Drug Event : Tolerability : Adverse Event : Serious Adverse Event (SAE) : Adverse Drug Reaction
6 Effect Modification (ADR) : Pharmacoepidemiology : : Drug Use Review : Medication Use Evaluation : Prospective : Concurrent : Retrospective : Ethical Pharmaceutical : Generic Drug : OTC : Prescription Drug : Line Extension Drug : Me-too Drug : Multiple Source Drug : Effective Patent Life : Biologics Effect Modification : Descriptive : Analytic : Risk Factors : Natural History : Case-Control Study : Cohort Study : Cross-sectional Study : Incidence Rate : Prevalence Rate : Mortality Rate : Fatality Rate : Odds Ratio : Risk Ratio : Pharmacoepidemiology : Socio-demographic Factors : Ecological Fallacy : Prospective Study : Relative Risk : Prospective Study : Relative Risk : Retrospective Study : Attributable Risk : Population Attributable Risk
7 (EMEA) (EMEA) (EMEA) (EMEA) EuroQoL Evidence Based Medicine Evidence Based Medicine Factor Analysis Spearman Food and Drug Administration (FDA) Gene Therapy Health Care Payers Health Care Payers Health Care Payers Health Care Payers Health Care Payment Systems Health Care Provider Health Care Provider Health Care Provider : Bias : Confounding (EMEA) (EMEA): Centralised Procedure (EMEA): Mutual Recognition Procedure (EMEA): Committee for Proprietary Medicinal Products (CMP) EuroQoL Evidence Based Medicine Evidence Based Medicine: Cochrane Collaboration Factor Analysis Spearman Food and Drug Administration (FDA) Gene Therapy : Health Technologies : Preventive Intervention : Diagnostic Intervention : Therapeutic Intervention : Medical Technology : Primary Preventive Interventions : Secondary Prevention : Secondary Preventive Interventions : Tertiary Preventive Interventions Health Care Payers Health Care Payers: Payers Health Care Payers: Single Party Payment System Health Care Payers: Third-Party Payment Health Care Payment Systems Health Care Provider Health Care Provider: Primary Care Provider Health Care Provider: Secondary Care
8 Health Care Provider Health Care Provider Health Economics Health Insurance Elements Health Insurance Elements Health Insurance Elements Health Insurance Elements Health Insurance Elements Health Insurance Elements Health Insurance Elements United States United States United States United States Health Policy Health Related Quality of Life (HRQOL) Health Status Health Status Health Status Health Status Health Status Health Technology Assessment Health Utilities Index Health Utilities Index Healthy Years Equivalent (HYE) Healthy Years Equivalent (HYE) Healthy Years Equivalent (HYE) Healthy Years Equivalent (HYE) HRQOL Incidence Incidence Incidence Provider Health Care Provider: Tertiary Care Provider Health Care Provider: Allied Health Personnel Health Economics Health Insurance Elements Health Insurance Elements: Premium Health Insurance Elements: Co-Paymen Health Insurance Elements: Deductible Health Insurance Elements: Third Party Administrator Health Insurance Elements: Benefit Design Health Insurance Elements: Certificate of Coverage United States United States: Medicaid United States: Medicare United States: Medicaid Prudent Pharmaceutical Purchasing Act (MPPPA) Health Policy Health Related Quality of Life (HRQOL) Health Status Health Status: Mortality Health Status: Morbidity Health Status: Health Status: Prognosis Health Technology Assessment Health Utilities Index Health Utilities Index: Cost- Analysis Healthy Years Equivalent Healthy Years Equivalent (HYE): Standard Gamble Healthy Years Equivalent (HYE): Time Trade-Off Healthy Years Equivalent (HYE): Decision Tree HRQOL Incidence Incidence: Incidence Rate Incidence: Incidence Density
9 Incidence Incidence Influence Diagrams Influence Diagrams Labeling (Labelling) Labeling (Labelling) Labeling (Labelling) Labeling (Labelling) Likelihood Ratio Likelihood Ratio Medical Device Monetary Value Monetary Value Monetary Value Monitoring Entities of s Monitoring Entities of s Monitoring Entities of s Incidence: Cumulative Incidence Incidence: Hazard Rate Influence Diagrams Influence Diagrams: Decision Analysis Labeling (Labelling) Labeling (Labelling): Label Labeling (Labelling): Off-Label Use Labeling (Labelling): Misbranding Likelihood Ratio Likelihood Ratio: Receiver Operating Characteristic (ROC) Curve : Health Maintenance Organization : Group Model HMO : Network HMO : Staff Model HMO : Preferred Provider Organization (PPO) : Individual Practice Association Medical Device : Stochastic : Deterministic : Sensitivity : Treatment Models : Evidence Model : Markov Models : Monte Carlo Simulation : Decision Trees : Influence Diagrams : Decision Analysis : Cost-Effectiveness Analysis : Meta Analysis Monetary Value Monetary Value: Constant Dollars Monetary Value: Current Dollars Monitoring Entities of s Monitoring Entities of s: Institutional Review Board Monitoring Entities of s: Data and Safety Monitoring Board
10 Monitoring Entities of s National Institute of Clinical Excellence (NICE) New Drug Application (NDA) New Drug Application (NDA) New Drug Application (NDA) New Drug Application (NDA) New Drug Application (NDA) Literature Review Overview Literature Review Overview Literature Review Overview Literature Review Overview Patient Reported Outcomes Patient Rights Monitoring Entities of s: Independent Data Monitoring Committee National Institute of Clinical Excellence (NICE) : Net health benefit : Net monetary benefit : Incremental net benefit : : Cost- : Cost-Benefit Analysis in Health Economics : Cost-Effectiveness Acceptability Curve New Drug Application (NDA) New Drug Application (NDA): Investigational New Drug Application New Drug Application (NDA): Approval Letter New Drug Application (NDA): Approvable Letter New Drug Application (NDA): Not approvable letter : Clinical Outcomes : Humanistic Intermediary : Economic Outcomes : Costs : humanistic Outcomes : Treatment modifiers Literature Review Overview Literature Review Overview: Literature Review Literature Review Overview: Systematic Review Literature Review Overview: Meta- Analysis Patient Reported Outcomes Patient Rights
11 Patient Study Recruitment Pharmacoeconomics Pharmacoepidemiology Pharmacoepidemiology Pharmacoepidemiology Pharmacoepidemiology Pharmacoepidemiology Pharmacoepidemiology Pharmacogenomics Pharmacogenomics Pharmacogenomics Pharmacokinetics Pharmacokinetics Pharmacokinetics Pharmacy Benefit Management Organization Predictive Value Predictive Value Predictive Value Predictive Value Predictive Value Prospective Studies Observational Studies Public Health Patient Study Recruitment Pharmacoeconomics Pharmacoepidemiology Pharmacoepidemiology: Epidemilogy Pharmacoepidemiology: Efficacy Pharmacoepidemiology: Effectiveness Pharmacoepidemiology: Compliance Pharmacoepidemiology: Channeling Pharmacogenomics Pharmacogenomics: Pharmacogenetics Pharmacogenomics: Predictive Medicine Pharmacokinetics Pharmacokinetics: Bioequivalence Pharmacokinetics: Bioavailability Pharmacy Benefit Management Organization Predictive Value Predictive Value: Negative Predictive Value Predictive Value: Positive Predictive Value Predictive Value: Sensitivity Predictive Value: Specificity Prospective Studies Observational Studies Public Health : Discounting : Standard Gamble : Time Trade-Off : Health Utilities Index : EuroQol EQ5D : Quality of Well-Being : : Measurement : Cost- Analysis : Disability-Adjusted Life Years (DALYs)
12 Quality Assurance (See also Quality of Care) Quality of Care (See also Quality Assurance) The Quality of Well-Being Scale (QWBS) Qualitative Research Qualitative Research Qualitative Research Qualitative Research Quantitative Research Rationing Reimbursement Reimbursement Reimbursement Reimbursement Reimbursement Reliability Reliability Reliability Reliability : Contingent Valuation Quality Assurance (See also Quality of Care) Quality of Care (See also Quality Assurance) The Quality of Well-Being Scale (QWBS) Qualitative Research Qualitative Research: Delphi Panel Qualitative Research: Focus Groups Qualitative Research: Open-ended Questions Quantitative Research Rationing Reimbursement Reimbursement: Co-payment Reimbursement: Co-insurance Reimbursement: Reimbursement per episode of illness Reimbursement: Per diem or per diem reimbursement Reliability Reliability: Inter-rater reliability Reliability: Test-retest reliability Reliability: Internal consistency : Sponsor : Funding agency : contracting agency : Contract Research Organization : Site : Trials management Organization : Coordinating Center : Coordinating Investigator : Steering Committee : Data Safety and Monitoring Board (DSMB) : Independent Data- Monitoring Committee (IDMC) : Practice Research Networks : Institutional Review Board, Human Subjects Committee
13 Responsiveness Responsiveness Responsiveness Responsiveness Retrospective Analysis Risk Risk Risk Risk Risk Adjustment Risk Adjustment Rosser Index Rosser Index Sample Selection Model Sensitivity Analysis Sensitivity Analysis Severity of Illness Short Form 36 (SF-36) Sickness Impact Profile Time-to-event models Time-to-event models Time-to-event models Time-to-event models Time-to-event models Time-to-event models Uncertainty : Ethics Committee : Institutional Review Board (IRB) : Human Subjects Committee Responsiveness Responsiveness: Distribution-based Responsiveness: Anchor-based methods Responsiveness: Minimal Clinical Importance Difference (MCID) Retrospective Analysis Risk Risk: Attributable Risk Risk: Population Attributable Risk Risk: Relative Risk Risk Adjustment Risk Adjustment: Risk Factors Rosser Index Rosser Index: -Weighed Indexes Sample Selection Model Sensitivity Analysis Sensitivity Analysis: Tornado Diagram Severity of Illness Short Form 36 (SF-36) Sickness Impact Profile : Parametric : Non Parametric : Descriptive : Inferential : Bayesian : Frequent : Parametric : Nonparametric Time-to-event models Time-to-event models: Cox regression model Time-to-event models: Life table Time-to-event models: Log-rank Time-to-event models: Survival Time-to-event models: Censoring Uncertainty
14 Measurement Measurement Measurement Validity Validity : -Weighted Index : Measurement : EuroQol : Health Index : Quality of Well-Being Scale : Cost- Analyses Measurement Measurement: Standard Gamble Measurement: Time Trade-Off Validity Validity: Validation : Cost-Benefit Analysis : Willingness-to-pay : Potential Pareto improvement : Contingent Valuation : Quality-Adjusted Life Years : Health-Year Equivalents : Maximin : Welfarist : Extra-welfarist
Introduction to Pharmacoeconomics. Almut G. Winterstein, Ph.D.
Introduction to Pharmacoeconomics Almut G. Winterstein, Ph.D. Why do we need Health Economics? Suppose you are comparing two drugs or services where one is more expensive than the other. In choosing the
Health Information Technology and Management
Health Information Technology and Management CHAPTER 9 Healthcare Coding and Reimbursement Pretest (True/False) CPT-4 codes are used to bill for disease and illness. Medicare Part B provides medical insurance
Reimbursement of Oncology Drugs in Saudi Arabia
Reimbursement of Oncology Drugs in Saudi Arabia Abdulaziz Al-Saggabi, B.Sc., M.Sc., Pharm.D. Director, Drug Policy & Economics Center Ministry of National Guard Health Affairs Chairman, ISPOR Arabic Network
PIP DATA FOR MARKET ACCESS
PIP DATA FOR MARKET ACCESS By Mark Nuijten, PhD, MD, MBA Maart 13, 2012 London, UK GENERAL TRENDS IN HEALTH CARE SYSTEMS IN EUROPE Health Care Systems Budget Constraints Inceasing demand for health care
Glossary. Last Reviewed 11/10/14
Glossary ACCC ACA ACS AHFS AHRQ AMA APC Association of Community Cancer Centers Affordable Care Act American Cancer Society American Hospital Formulary Service Agency for Healthcare Research and Quality
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS. (project)
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS Ewa Orlewska 1, Piotr Mierzejewski 1,2 (project) 1 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw Head
THE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT
1 THE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT Association of Corporate Counsel Legal Quick Hit September 6, 2011 Maria E. Gonzalez Knavel Partner Foley & Lardner LLP 414.297.5649
TECHNICAL APPENDIX 1 THE FUTURE ELDERLY MODEL
TECHNICAL APPENDIX 1 THE FUTURE ELDERLY MODEL To estimate the potential health benefits of PCSK9 inhibitors, we use the Future Elderly Model (FEM), a dynamic microsimulation model developed by Goldman
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis Sullivan P W, Follin S L, Nichol M B
Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis Sullivan P W, Follin S L, Nichol M B Record Status This is a critical abstract of an economic evaluation that
James C. Robinson Kaiser Permanente Professor of Health Economics Director, Berkeley Center for Health Technology University of California, Berkeley
James C. Robinson Kaiser Permanente Professor of Health Economics Director, Berkeley Center for Health Technology University of California, Berkeley Public policy: Congress and Obama Administration Challenges
PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE
PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE Moderator Audrey Halvorson, Vice Chairperson, Health Practice Council Presenters Karen Bender, Member, Prescription Drug
Glossary. Adults: Individuals ages 19 through 64. Allowed amounts: See prices paid. Allowed costs: See prices paid.
Glossary Acute inpatient: A subservice category of the inpatient facility clams that have excluded skilled nursing facilities (SNF), hospice, and ungroupable claims. This subcategory was previously known
Contents. Page. Chapter
Contents Chapter I. Summary and Policy Options........................................ 3 2. Physician Payment Under the Medicare Program: Problems and Changing Context...................................................
KEEPING PRESCRIPTION DRUGS AFFORDABLE: The Value of Pharmacy Benefit Managers (PBMs)
The Texas Association of Health Plans Representing health insurers, health maintenance organizations, and other related health care entities operating in Texas. KEEPING PRESCRIPTION DRUGS AFFORDABLE: The
Managing Specialty Pharmaceuticals: Balancing Access and Affordability
Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President
Office of Compliance Services. Revenue Cycle and Billing Terminology and Definitions
Revenue Cycle and Billing Terminology and Definitions Advance Beneficiary Notice (ABN) Adjustment (aka write off ) Allowed amount Ancillary Service Appeal Authorization Centers for Medicare & Medicare
Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy
Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES
REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax:
REQUEST FOR MEDICARE PRESCRIPTION DRUG COVERAGE DETERMINATION This form may be sent to us by mail or fax: Address: Fax Number: Aetna Better Health of Virginia (HMO SNP) 1-877-270-0148 Part D Coverage Determination
Table of Contents. 1.0 Description of the Procedure, Product, or Service Definitions... 1
Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Definitions... 1 2.0 Eligibility Requirements... 1 2.1 Provisions... 1 2.1.1 General... 1 2.1.2 Specific... 1 2.2 Special
Provider Manual Amendments
Amendments L.A. Care Health Plan Revised 11/2015 lacare.org LA1478 11/15 16.0 Pharmacy Overview L.A. Care s prescription drug formulary is designed to support the achievement of positive member health
LARGE SIMPLE CLINICAL TRIALS IN INSURANCE SYSTEMS POST-MYOCARDIAL INFARCTION FREE RX EVENT AND ECONOMIC EVALUATION (MI FREEE) TRIAL
LARGE SIMPLE CLINICAL TRIALS IN INSURANCE SYSTEMS POST-MYOCARDIAL INFARCTION FREE RX EVENT AND ECONOMIC EVALUATION (MI FREEE) TRIAL Niteesh K. Choudhry, MD, PhD Associate Professor, Harvard Medical School
Putting the Pieces Together, a Review of the Benefits Investigation Process. Thomas Cohn, Asembia
Putting the Pieces Together, a Review of the Benefits Investigation Process Thomas Cohn, Asembia Introductions Thomas Cohn Chief Strategy Officer Asembia Tony Scheuth CEO and Managing Partner Point-of-Care
Cigna Administrative Policy
Cigna Administrative Policy Subject Clinical Trials Table of Contents Administrative Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/15/2014 Administrative
UPDATED IAA EDUCATION SYLLABUS
II. UPDATED IAA EDUCATION SYLLABUS A. Supporting Learning Areas 1. STATISTICS Aim: To enable students to apply core statistical techniques to actuarial applications in insurance, pensions and emerging
UC SHIP Premium Formulary. Effective September 1, 2016
UC SHIP Premium Formulary Effective September 1, 2016 Formulary A formulary identifies the drugs available for certain conditions and organizes them into cost levels, also known as tiers. An important
Innovative Strategies for Managing the Rising Cost of Specialty Drugs
Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs
Effective: July 1, 2015 Group Number:
SUMMARY OF MATERIAL MODIFICATIONS To the Summary Plan Description for Valley Schools Employee Benefits Trust Choice Plus HDHP 2600 Gold Plan Tolleson Union High School Effective: July 1, 2015 Group Number:
Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy
Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - In this Section there are references unique to Blue Essentials, Blue Advantage HMO and Blue Premier. These network specific
Project Theft Management,
Project Theft Management, by applying best practises of Project Risk Management Philip Rosslee, BEng. PrEng. MBA PMP PMO Projects South Africa PMO Projects Group www.pmo-projects.co.za philip.rosslee@pmo-projects.com
Chapter 7 General Billing Rules
7 General Billing Rules Reviewed/Revised: 10/10/2017, 07/13/2017, 02/01/2017, 02/15/2016, 09/16/2015, 09/18/2014 General Information This chapter contains general information related to Health Choice Arizona
Comprehensive Primary Care Payment Calculator User s Guide
1 Comprehensive Primary Care Payment Calculator User s Guide Prepared by Health Data Decisions August 2017 Disclaimer: Information provided in connection with this calculator by FMAHealth and its contributors
HTA and Submissions. Ferg Mills, Angela Rocchi April 5, Agenda
HTA and Submissions Ferg Mills, Angela Rocchi April 5, 2017 Agenda The Decision Problem Role of HTA bodies in Canada CADTH, pcodr and INESSS Overview of the elements of the HTA submission Clinical package
Methodology to assess the cost impact of PMB benefit definitions
Methodology to assess the cost impact of PMB benefit definitions Version 1.0.0 07 March 2012 Contents 1 Background... 1 2 Aim... 1 3 Objectives... 1 4 Methods... 2 5 Variables for data collection, data
Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals
Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals By Cindy Parks Thomas, Ph.D. A dvances in biotechnology have brought many effective new treatments for serious and debilitating
AN OVERVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH
Int. J. LifeSc. Bt & Pharm. Res. 2012 Harika Javangula, 2012 Review Article ISSN XXXX-XXXX www.ijlbpr.com Vol.1, Issue. 1, January 2012 2012 IJLBPR. All Rights Reserved AN OVERVIEW OF PHARMACOECONOMICS
Pre Market Reimbursement Strategies for New Technologies
Pre Market Reimbursement Strategies for New Technologies Marilyn Denegre-Rumbin, JD MBA Director Payer-Reimbursement Strategy Strategy & Business Development December 1, 2015 Early Strategy Integration
The Fundamentals of Reimbursement
The Fundamentals of Reimbursement Understanding How Coverage, Coding, and Payment Impact a Medical Technology Kelli Hallas Executive Vice President of Reimbursement Emerson Consultants, Inc. OMTEC June
Clinical Trials Corporate Medical Policy
Clinical Trials Corporate Medical Policy File name: Clinical Trials File code: UM.GEN.02 Origination: 12/31/2013 Last Review: 03/2017 Next Review: 03/2018 Effective Date: 06/01/2017 Description This medical
Using Predictive Analytics to Better Understand Morbidity
International Insights on Mortality, Population and the Public Interest Tuesday, October 3, 2017 Westin River North Hotel, Chicago IL Using Predictive Analytics to Better Understand Morbidity Merideth
Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007
Prescription Drugs Spending Distribution and Cost Drivers Steve Kappel January 25, 2007 Introduction Why Focus on Drugs? Compared to other health care spending: Even faster annual growth Higher reliance
The HPfHR 3-Tier System
The HPfHR 3-Tier System The basic level (Tier 1) of the new healthcare system would cover the entire population- from cradle to grave and would include, based on evidenced based data, all medical, surgical
Physical Medicine & Rehabilitation: Multiple Therapy Procedure Reduction Policy
Policy Number 2018R0121B Physical Medicine & Rehabilitation: Procedure Reduction Policy Annual Approval Date 3/08/2017 Approved By Reimbursement Policy Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT
Basics of Developing Study Budgets in Clinical Research
Basics of Developing Study Budgets in Clinical Research Office of Research Administration (ORA) Tatyana Vikhlyantseva, BS, CPCO, CCS-P, CPC Sr. Manager, Pre-Award Services Learning Objectives Recognize
Subject CS2A Risk Modelling and Survival Analysis Core Principles
` Subject CS2A Risk Modelling and Survival Analysis Core Principles Syllabus for the 2019 exams 1 June 2018 Copyright in this Core Reading is the property of the Institute and Faculty of Actuaries who
Oklahoma Health Care Authority
Oklahoma Health Care Authority It is very important that you provide your comments regarding the proposed rule change by the comment due date. Comments are directed to Oklahoma Health Care Authority (OHCA)
Overview of Coverage of Drugs Under the Medicaid Medical Benefit
Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008 Amanda Bartelme Avalere Health LLC Avalere Health LLC The intersection of business strategy and public policy Medical vs. Pharmacy
Economic Evaluations in Health An introduction for clinicians, researchers, and policy makers
Economic Evaluations in Health An introduction for clinicians, researchers, and policy makers Philip Leonard, PhD, MSSU and UNB Economics May 16, 2016 Saint John Regional Hospital, NB Economics in health
PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES
PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES We at Sanofi work passionately, every day, to understand and solve health care needs of people across the world. We are dedicated to therapeutic
Understanding Your Prescription Program. CCIU Employee Meeting September 7, 2016
Understanding Your Prescription Program CCIU Employee Meeting September 7, 2016 Welcome to FutureScripts! Founded in 2006 Philadelphia presence Strong ties to community and local businesses 68,000 pharmacies
Glossary. Chapter 7 Individual-level drug utilization analyses. Chapter 8 Measurement of drug expenditure
Glossary Chapter 7 Individual-level drug utilization analyses Incidence rate Used in epidemiology to express the rate of newly diseased in a population. For example, the incidence rate of insulin use is
Article from. Predictive Analytics and Futurism. June 2017 Issue 15
Article from Predictive Analytics and Futurism June 2017 Issue 15 Using Predictive Modeling to Risk- Adjust Primary Care Panel Sizes By Anders Larson Most health actuaries are familiar with the concept
RULES OF DEPARTMENT OF COMMERCE AND INSURANCE DIVISION OF INSURANCE AND DIVISION OF TENNCARE
RULES OF DEPARTMENT OF COMMERCE AND INSURANCE DIVISION OF INSURANCE AND DIVISION OF TENNCARE CHAPTER 0780-1-73 UNIFORM CLAIMS PROCESS FOR TENNCARE PARTICIPATING TABLE OF CONTENTS 0780-1-73-.01 Authority
DO YOU SPEAK MEDICARE PART D?
CMA WEEKLY ALERT JULY 21, 2005 DO YOU SPEAK MEDICARE PART D? In the next few months the older people and people with disabilities who rely on Medicare, along with their families, friends, and advocates,
Prescription Drug Rider
Prescription Drug Rider P L A N C E R T I F I C A T E Drug 516 Jan 2014 01:14 HMSA s Prescription Drug Rider This summary is intended to provide a condensed explanation of plan benefits. Certain limitations,
Medicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014
Medicaid Prescribed Drug Program Spending Control Initiatives For the Quarter April 1, 2014 through June 30, 2014 Report to the Florida Legislature January 2015 Table of Contents Purpose of Report... 1
Discarded Drugs and Biologicals
Policy Number Discarded Drugs and Biologicals DDB01012011RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 03/26/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is
Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications
AMCP Partnership Forum Designing Benefits and Payment Models for Innovative High Investment Medications Welcome Bri Palowitch, PharmD, BCGP Manager, Pharmacy Affairs Academy of Managed Care Pharmacy Disclaimer
Re: Medicare Prescription Drug Benefit Manual Draft Chapter 6
September 26, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare & Medicaid Services Mail Stop C4-13-01 7500 Security Boulevard Baltimore, MD 21244
Following is a list of common health insurance terms and definitions*.
Health Terms Glossary Following is a list of common health insurance terms and definitions*. Ambulatory Care Health services delivered on an outpatient basis. A patient's treatment at a doctor's office
Recommendations of the Panel on Cost- Effectiveness in Health and Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
Track III-A. Creating Relationships with Prescription Drug Plans and Managed Care Organizations
Track III-A Creating Relationships with Prescription Drug Plans and Managed Care Organizations David L. Ralston Legal Director Schering-Plough Corporation Part D is for Dollars Follow the money by tracing
Glossary of Terms (Terms are listed in Alphabetical Order)
Glossary of Terms (Terms are listed in Alphabetical Order) Access Access refers to the availability and location of pharmacies that participate in the network that serves your pharmacy benefit plan. Acute
Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
HIPAA Readiness Disclosure Statement
HIPAA Readiness Disclosure Statement Blue Cross of California and its affiliates have been diligently following the evolution of the Administrative Simplification provisions of the Health Insurance Portability
Medicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Investigational (Experimental) Services Origination: November 2009 Review Date: July 12, 2017 Next Review: July 2019 DESCRIPTION OF PROCEDURE OR SERVICE Title XVIII
Title: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12
Title: Financial Conflicts of Interest Department: Research Institute Effective Date: 3/18 Reviewed: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12 Policy & Procedure Replaces: Disclosure of Conflicts
Drug Royalty II $701,420,000. Presentation to: San Diego County Employees Retirement Association
Drug Royalty II $701,420,000 Presentation to: San Diego County Employees Retirement Association November 2010 Profile Business Model Team Investment Criteria To acquire Royalty Streams on established commercialized
Health Service Reimbursement: Early Benefit Assessment of New Drugs in Germany. Conflict of interest. Nothing to disclose
Health Service Reimbursement: Early Benefit Assessment of New Drugs in Germany 19th Congress of the EAHP Barcelona, 26-28 March 2014 Katrin Nink Conflict of interest Nothing to disclose (Research Associate
Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence
Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence Eleni Samaras Allen, PharmD March 22, 2016 Kissimmee, FL Disclaimer The views and opinions expressed in the following PowerPoint
Re: Medicare Prescription Drug Benefit Manual Draft Chapter 5
September 18, 2006 BY ELECTRONIC DELIVERY Cynthia Tudor, Ph.D. Director, Medicare Drug Benefit Group Centers for Medicare and Medicaid Services Department of Health and Human Services Mail Stop C4-13-01
Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
Presented by: Steven Flores. Prepared for: The Predictive Modeling Summit
Presented by: Steven Flores Prepared for: The Predictive Modeling Summit November 13, 2014 Disease Management Introduction A multidisciplinary, systematic approach to health care delivery that: Includes
Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]
![Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]](/thumbs/88/115848006.jpg "Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]")
January 25, 2019 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P P.O. Box 8013 Baltimore, MD 21244-8013 Re: Modernizing
Overview of the BCBSRI Prescription Management Program
Overview of the BCBSRI Prescription Management Program A. Prescription Drugs Dispensed at a Pharmacy This plan covers prescription drugs listed on the Blue Cross & Blue Shield RI (BCBSRI) formulary and
Glossary of Healthcare Terminology
Glossary of Healthcare Terminology Accredited (Accreditation): Being accredited means that a facility has met certain quality standards. These standards are set by private, nationally recognized groups
Session 3: Determining Healthcare Costs in the United States
Session 3: Determining Healthcare Costs in the United States Blythe Adamson, MPH, PhDc Pharmaceutical Outcomes Research and Policy Program with support from Dr. Carrie Bennette who provided a large part
Leveraging Real-World Data and Analytics in the Device Industry. Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics
Leveraging Real-World Data and Analytics in the Device Industry Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics Agenda 1. Overview 2. What is Real World Data (RWD)? 3. How is RWD Currently
ECONOMIC ANALYSIS IN HEALTH CARE
ECONOMIC ANALYSIS IN HEALTH CARE Second Edition Stephen Morris Nancy Devlin David Parkin and Anne Spencer WILEY A John Wiley and Sons, Ltd, Publication Preface xiii Chapter 1 Introduction to economic analysis
Coverage and Billing Issues for Clinical Research
Coverage and Billing Issues for Clinical Research John E. Steiner, Jr., Esq Chief Compliance Officer Cleveland Clinic Health System Cleveland, Ohio The Second Annual Medical Research Summit Washington,
Kroll Ontrack, LLC Prescription Drug Plan. Plan Document and Summary Plan Description
Kroll Ontrack, LLC Prescription Drug Plan Plan Document and Summary Plan Description Effective December 9, 2016 Kroll Ontrack, LLC reserves the right to amend the Kroll Ontrack, LLC Health & Welfare Plan
MELINTA THERAPEUTICS, INC. (Exact name of registrant specified in its charter)
3 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
Health Plan Approach to Operationalizing a Specialty Drug Management Program
Health Plan Approach to Operationalizing a Specialty Drug Management Program Mesfin Tegenu, MS, RPh Abstract BACKGROUND: Expenditures related to specialty drugs consume a significant percentage of available
UnitedHealthcare Choice Plus. United HealthCare Insurance Company. Certificate of Coverage
UnitedHealthcare Choice Plus United HealthCare Insurance Company Certificate of Coverage For the Definity Health Savings Account (HSA) Plan 7PC of East Central College Enrolling Group Number: 711369 Effective
Recent Developments In U.S. Pharmaceutical Pricing: The Case Example Of The Proposed Medicare Part B Experiment
Recent Developments In U.S. Pharmaceutical Pricing: The Case Example Of The Proposed Medicare Part B Experiment Presentation by Susan Dentzer President and CEO, NEHI (Network for Excellence in Health Innovation)
Compensation and Reimbursement
492 Pharmacy Management: Compensation and Reimbursement Positions Compensation and Reimbursement Revenue Cycle Compliance and Management (1710) To encourage pharmacists to serve as leaders in the development
Assessing post-marketing safety of authorized generic products
Assessing post-marketing safety of authorized generic products Rishi J Desai, MS, PhD Division of Pharmacoepidemiology & Pharmacoeconomics Brigham & Women s Hospital Background Authorized generics (AGs)
Quick Guide to Secondary Claims
Quick Guide to Secondary Claims Would you like to: Please click below what you would like help with to be directed to that specific section in this guide. Convert your primary claim to a secondary claims
CHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT
CHAPTER 58-29E PHARMACY BENEFITS MANAGEMENT 58-29E-1. Definition of terms. Terms used in this chapter mean: (1) "Covered entity," a nonprofit hospital or medical service corporation, health insurer, health
Value-Based Pricing: The Good, The Bad, and The Ugly
Value-Based Pricing: The Good, The Bad, and The Ugly Medical Device Regulatory, Reimbursement and Compliance Congress March 27, 2008 Randel E. Richner, BSN, MPH President, Founder Reform There is no problem,
Get the most out of your pharmacy benefit.
Get the most out of your pharmacy benefit. The ins and outs of managing pharmacy costs (and how the right information can lead to big savings). Learn more about the Artemis Platform at: artemishealth.com
New Options in Medicare Advantage: Addressing the Social Determinants of Health and More
New Options in Medicare Advantage: Addressing the Social Determinants of Health and More Over the last year, new laws, regulations, and guidance from the Centers for Medicare & Medicaid Services (CMS)
CBI Pharmaceutical Compliance Congress Washington, D.C.
Risks Associated with the Hub CBI Pharmaceutical Compliance Congress Washington, D.C. April 28, 2017 Disclaimer On behalf of this panel, please note that the views and opinions that will be expressed during
Healthcare professionals make hyaluronic acid work.
2018 Reimbursement Guide Healthcare professionals make hyaluronic acid work. Reimbursement Code J7320 orthogenrx.com In a field where hyaluronic acids are often considered to be the same, GenVisc 850 is
XPressClaim Help. Diagnosis 1,2,3,etc. Enter the number(s) of the corresponding diagnosis code(s) that applies to this service.
Keying Information Professional Claims CMS 1500 Claim type Please select the type of claim: 1- Original claim 7- Replacement of prior claim Please note: 7- Replacement of prior claim should only be selected
Chapter 8 Section 9.1
Other Services Chapter 8 Section 9.1 Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and
Outpatient Prescription Drug Benefits
Outpatient Prescription Drug Benefits Supplement to Your HMO/POS Evidence of Coverage Summary of Benefits Member Calendar Year Brand Drug Deductible Per Member Applicable to all covered Brand Drugs, including
Sponsored by: Approved instructor
Sponsored by: Approved About the Speaker Nancy M Enos, FACMPE, CPMA CPC-I, CEMC is an independent consultant with the MGMA Health Care Consulting Group. Mrs. Enos has 40 years of experience in the practice
Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare
Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning
Planning and conducting claims data analyses: the example of German claims data analyses
Ingress White Papers No. 2 Planning and conducting claims data analyses: the example of German claims data analyses by Thomas Wilke Ingress health: our vision We strongly believe that the future of health
POLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations
PAGE: 1 of 6 SCOPE: Centene Corporate Pharmacy Solutions, Health Plan Pharmacy Departments, Centene Pharmacy and Therapeutics Committee, Health Plan Pharmacy and Therapeutics Committees, Envolve Pharmacy